Publications

Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LFelipe, de Henau O, Gigoux M et al..  2021.  Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma.. Cell Rep. 34(2):108620.

Chakraborty S, Zappasodi R.  2021.  To Go or Not to Go?-Targeting Tregs Traveling in Tumors. Cancer Res. 81(11):2817-2819.

Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I et al..  2021.  Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors.. Immunity. 54(7):1561-1577.e7.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G et al..  2020.  B cells and tertiary lymphoid structures promote immunotherapy response.. Nature. 577(7791):549-555.

Campesato LFelipe, Budhu S, Tchaicha J, Weng C-H, Gigoux M, Cohen IJose, Redmond D, Mangarin L, Pourpe S, Liu C et al..  2020.  Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.. Nat Commun. 11(1):4011.

Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, Mohmood SRaza, Fernández-García J, Tsai C-H, Schulze I et al..  2020.  CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.. Nat Immunol. 21(3):298-308.

Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL et al..  2020.  Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.. J Immunother Cancer. 8(1)

Zappasodi R, Budhu S, Abu-Akeel M, Merghoub T.  2020.  In vitro assays for effector T cell functions and activity of immunomodulatory antibodies.. Methods Enzymol. 631:43-59.

Sellam LSarah, Zappasodi R, Chettibi F, Djennaoui D, Mesbah NYahi-Ait, Amir-Tidadini Z-C, Touil-Boukoffa C, Ouahioune W, Merghoub T, Bourouba M.  2020.  Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism.. Arch Biochem Biophys. 690:108479.